Oral nonpeptide GLP-1 receptor agonistEli Lilly

Orforglipron

Orforglipron is an oral, nonpeptide GLP-1 receptor agonist from Eli Lilly. As a once-daily pill it could broaden access to incretin-based weight loss beyond injectables, including weight maintenance after switching from semaglutide or tirzepatide.

Forecast a trial in the ArenaBrowse all benchmarks
1
Trials tracked
0
Resolved
1
Indications
1
Targets

Orforglipron forecasting benchmarks

1 benchmark
OpenPhase 3

ATTAIN-MAINTAIN (orforglipron) weight maintenance after switching from Wegovy or Zepbound

Orforglipron · Obesity

Dec 18, 2025Clinical Trials

Mechanism & molecular targets

GLP-1R· gene

Indications studied

Obesity

Developed by

Eli Lilly· LLY

About Orforglipron

What is Orforglipron?

Orforglipron is an oral, nonpeptide GLP-1 receptor agonist from Eli Lilly. As a once-daily pill it could broaden access to incretin-based weight loss beyond injectables, including weight maintenance after switching from semaglutide or tirzepatide. It is a oral nonpeptide glp-1 receptor agonist developed by Eli Lilly.

What does Orforglipron target?

Orforglipron acts on GLP-1 receptor (GLP1R).

How well do AI models predict Orforglipron trial outcomes?

Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.

Keep exploring

All benchmarksDiseasesCompaniesTargets & genes